NicholasJRobertMD

Oncology • Fairfax, VA

Breast Cancer, Hematologic Oncology

Virginia Cancer Specialists

Join to view full profile

Dr. Robert is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Robert's full profile

Already have an account?

Office
8503 Arlington Blvd
Ste 400
Fairfax, VA 22031
Phone+1 703-280-5390

Fax+1 703-280-9596

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1980 - 1981
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1979 - 1980
Massachusetts General HospitalResidency, Pathology-Anatomic and Clinical, 1976 - 1978
McGill University Faculty of MedicineClass of 1974

Certifications & Licensure

VA State Medical License 1991 - 2020
American Board of Pathology Anatomic Pathology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Top Doctors:Washington DC Area Castle Connolly, 2012
Northern Virginia Magazine Castle Connolly, 2007-2008
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Letrozole After Tamoxifen in Treating Women With Breast Cancer Start of enrollment: 1998 Aug 24
Completed
Phase 3
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2009 Sep 10
Completed
Phase 3
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Start of enrollment: 2009 Dec 01
Completed
Phase 1, Phase 2
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Completed
Phase 3
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Start of enrollment: 2013 May 21
Completed
Phase 2
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer Start of enrollment: 2013 Aug 01
Completed
Not Applicable
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
David M. Waterhouse, E. Nwokeji, Marley Boyd, John R. Penrod, Janet L. Espirito
Future Oncology. 2021-03-26
2117 citations
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progr...
Melody A. Cobleigh, Charles L. Vogel, Debasish Tripathy, Nicholas J. Robert, Susy Scholl
Journal of Clinical Oncology. 1999-09-01
5559 citations
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe, R. Abe, K. Enomoto, K. Kikuchi, H. Koyama
Lancet. 2005-05-14

Abstracts/Posters

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting
Nicholas James Robert, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Personalized Care in the Community: Making It HappenDecember 19th, 2022
New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology SettingJune 6th, 2022
Ontada Research Highlights Power of Real-World Oncology Data at ISPOR 2022May 26th, 2022
Join now to see all